Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Heparin seizure

This article was originally published in The Gray Sheet

Executive Summary

FDA seizes 11 lots of tainted heparin Nov. 6, including some of the type used in medical devices, from Cincinnati-based Celsus Laboratories. The over-sulfated chondroitin contaminant identified in the seized product has previously been fingered as the cause of deaths and adverse events in supplies of the blood-thinning agent imported from China (1"The Gray Sheet" June 9, 2008, In Brief). Six of the seized lots were heparin lithium, used in vacutainer blood collection tubes, some in vitro diagnostics and as a coating for capillary tubes. The other five were pharmaceutical grade

You may also be interested in...

Deaths linked to heparin-containing devices

FDA received reports of 11 deaths and 86 non-fatal adverse events associated with heparin-containing devices between Jan. 1 and May 14, 2008, according to a June 3 notice. The agency, which did not release the brands of the devices involved in the reports, says it has not determined conclusively that contaminated heparin caused the events. Most of the reports (82%) were associated with heparin lock flush solutions, such as the type Baxter recalled in January (Hep-Lock) due to heparin contamination. Other implicated devices include heparin-coated oxygenators and circuits used during bypass procedures and heparin-coated vascular grafts. Medtronic recalled heparin-coated cardiopulmonary bypass devices last month, but the firm had not received any adverse event reports for the products (1"The Gray Sheet" May 12, 2008, p. 3). The agency also notes that in vitro diagnostics tests that monitor heparin injected into patients or use tubes containing heparin to collect unclotted blood might also be impacted by the contamination, though no problems have been reported to date

Biopharma Quarterly Dealmaking Statistics, Q4 2019

Financing for biopharma companies increased by 19% in Q4 to $15.8bn. M&A value quadrupled, compared with Q3, thanks to nine billion-dollar-plus transactions, led by the buy-out of Nestle Skin Health, now Galderma.Among the key alliances of Q4 were recurring themes of gene therapy and oncology, but also big investments in oligonucleotide technologies.

Europe Restricts Cyproterone Use Due To Meningioma Risk; Companies To Conduct Studies

The risk of developing meningioma with cyproterone-containing medicines is rare, but it is serious enough to merit restrictions on how such products are used, according to the European Medicines Agency.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts